RSS feeds allow Web site content to be gathered via feed reader software. Click the subscribe link to obtain the feed URL for this page. The feed will update when new content appears on this page.

Allergan Inc.

A collection of news and information related to Allergan Inc. published by this site and its partners.

Top Allergan Inc. Articles

Displaying items 1-11
  • Allergan board rejects latest Valeant offer

    The board of Botox maker Allergan Inc. unanimously rejected an increased buyout offer from a Canadian pharmaceutical company as the closely watched acquisition effort showed no signs of a resolution. Valeant Pharmaceuticals International Inc. last month...
  • Ackman, Valeant partnering in bid to acquire Botox maker Allergan

    Ackman, Valeant partnering in bid to acquire Botox maker Allergan
    Activist investor Bill Ackman is partnering with Valeant Pharmaceuticals in an attempt to buy Orange County pharmaceutical company Allergan Inc., which sells the popular wrinkle treatment Botox. Ackman’s Pershing Square Capital Management said...
  • Ackman, Valeant partner in bid to buy Botox maker Allergan

     Ackman, Valeant partner in bid to buy Botox maker Allergan
    Activist investor Bill Ackman is partnering with a Canadian pharmaceutical company in an effort to buy Allergan Inc., the Irvine company that makes the popular wrinkle treatment Botox. Ackman and Valeant Pharmaceuticals International Inc. have already...
  • Ackman and Valeant make bid for Allergan

    Ackman and Valeant make bid for Allergan
    Activist investor Bill Ackman and his unlikely Canadian partner, Valeant Pharmaceuticals International Inc., unveiled details of their bid for Irvine pharmaceutical company Allergan Inc., which makes the popular Botox wrinkle treatment. Valeant will...
  • Novartis, GSK announce multibillion-dollar overhaul of drug businesses

    Novartis, GSK announce multibillion-dollar overhaul of drug businesses
    Swiss pharmaceutical titan Novartis AG on Tuesday announced an overhaul of its operations that involved several multibillion-dollar deals with GlaxoSmithKline intended to allow Novartis to focus on its oncology business and boost profitability, the...
  • Allergan says it 'will carefully review' Valeant offer

    Allergan says it 'will carefully review' Valeant offer
    Allergan Inc., the Irvine company that makes popular wrinkle treatment Botox, acknowledged Tuesday that it has received a buyout offer from Valeant Pharmaceuticals International Inc. The company said the offer from the Canadian drug maker was...
  • Allergan stock climbs amid $46-billion bid

     Allergan stock climbs amid $46-billion bid
    Canadian company Valeant Pharmaceuticals International Inc. and activist investor Bill Ackman moved forward with their plans to acquire Botox maker Allergan Inc., offering shareholders about $46 billion and touching off what could be a contentious fight....
  • Allergan adopts 'poison pill' defense in Valeant takeover bid

    Allergan Inc., the Irvine company that makes Botox, has adopted a "poison pill" defense that could make it more difficult for Canadian company Valeant Pharmaceuticals International Inc. and activist investor Bill Ackman to force through a takeover bid....
  • Allergan questions viability, experience of would-be buyer Valeant

    A day before would-be buyer Valeant Pharmaceuticals is set to unveil a second, unsolicited takeover bid, its acquisition target, Allergan Inc., sought to discredit the company by filing a presentation with regulators questioning the viability of Valeant's...
  • Allergan steps up attack on Valeant

    The billion-dollar takeover battle targeting Irvine-based Allergan is heading into high gear this week with both sides on the attack. On Tuesday, Allergan Inc., the maker of Botox, launched a broadside against Canadian rival Valeant Pharmaceutics...
  • New Valeant bid for Botox maker Allergan 'disappointing,' analyst says

    New Valeant bid for Botox maker Allergan 'disappointing,' analyst says
    Valeant on Wednesday boosted its cash-stock offer to buy Irvine company and Botox maker Allergan to $58.30 a share, raising the cash portion by $10, in a deal now worth about $50 billion.  The Canadian company offered its second, improved bid in the...